18 August 2023 in Cell Death & Disease
Ferroptosis, a form of programed cell death, can be promoted by inhibitors of the xCT transporter (erastin) or GPX4 (RSL3). We found that GPX4, but not the xCT transporter, is selectively elevated in luminal breast cancer. Consistent with this observation, the majority of luminal breast cancer cell lines are exquisitely sensitive to RSL3 with limited sensitivity to erastin. In RSL3-resistant, but not sensitive, luminal breast cancer cell lines, RSL3 induces HER2 pathway activation. Irreversible HER2 inhibitors including neratinib reversed RSL3 resistance in constitutively RSL3-resistant cell lines. Combination treatment with RSL3 and neratinib increases ferroptosis through mitochondrial iron-dependent reactive oxygen species production and lipid peroxidation. RSL3 also activated replication stress and concomitant S phase and G2/M blockade leading to sensitivity to targeting the DNA damage checkpoint. Together, our data support the exploration of RSL3 combined with irreversible HER2 inhibitors in clinical trials.
4 September 2025 in Cancer Letters
Gemcitabine, a ribonucleotide reductase (RNR) inhibitor, is active in pancreatic ductal carcinoma (PDAC) patients, but unfortunately has a limited impact on long term outcomes. Gemcitabine induces nucleotide deficiency, DNA damage including single stranded DNA (ssDNA) and replication stress (RS). DNA damage can activate cyclic GMP-AMP synthase (cGAS), leading to genome instability, micronucleus generation, and immune activation. In model systems, gemcitabine resistance can be overcome by combination treatment with the ataxia telangiectasia and Rad3-related inhibitor (ATRi; AZD6738) that blocks S and G2 checkpoints, although underlying mechanisms remain to be fully elucidated. We show that cells with low basal RS are resistant to gemcitabine, which could be overcome by combination treatment with AZD6738 through elevation of RS, phospho-RPA32 exhaustion, and mitotic catastrophe in PDAC cell models. Gemcitabine induces nuclear cGAS accumulation independent of STING-mediated immune activation. The binding of nuclear cGAS to γH2AX at double strand DNA breaks (DSBs) plays a pivotal role in RS activation and mitotic catastrophe in gemcitabine and AZD6738 treated cells.
24 February 2023 in Research Square
Ferroptosis, a form of programed cell death, can be promoted by inhibitors of the xCT transporter (erastin) or GPX4 (RSL3). GPX4, but not the xCT transporter, is selectively elevated in luminal breast cancer. Consistent with this observation, the majority of luminal breast cancer cell lines are exquisitely sensitive to RSL3 with limited sensitivity to erastin. In RSL3 resistant, but not sensitive, luminal breast cancer cell lines, RSL3 induces HER2 pathway activation. Irreversible HER2 inhibitors including neratinib reversed RSL3 resistance in constitutively RSL3-resistant cell lines. Combination treatment with RSL3 and neratinib increases ferroptosis through mitochondrial iron-dependent reactive oxygen species production and lipid peroxidation. RSL3 also activated replication stress and concomitant S phase and G2/M blockade leading to sensitivity to targeting the DNA damage checkpoint. Together, our data supports exploration of RSL3 combined with irreversible HER2 inhibitors in clinical trials.
29 September 2026 in Cellular Oncology
Background The bromodomain and extra-terminal (BET) protein family, especially the bromodomain-containing protein 4 (BRD4), drives tumor progression. BET inhibitors (BETi) have shown therapeutic potential, although challenges remain. Exploring the downstream targets of BET inhibition is crucial for advancing precision cancer therapies. This study aimed to explore the downstream molecular targets of BETi using proteomics and to provide mechanistic insights that could support the development of precision cancer therapies. Methods Reverse phase protein array (RPPA) and western blotting (WB) were performed to investigate the downstream molecular targets of BRD4 inhibitors (BRD4i). Chromatin immunoprecipitation (ChIP) sequencing in the GSE63581 dataset and quantitative reverse transcription polymerase chain reaction (RT-qPCR) were used to assess transcriptional regulation following BRD4i treatment. Methylation analyses of stimulator of interferon genes (STING) in the CCLE and TCGA datasets, WB, and chromatin immunoprecipitation-quantitative polymerase chain reaction (ChIP-qPCR) were performed to explore the epigenetic impacts after BRD4i treatment. In vivo and in vitro immune responses were evaluated using type I interferon assays, cytokine measurements, and syngeneic mouse models. Results BET inhibition significantly suppressed STING expression by targeting its promoter and enhancer regions, thereby reducing downstream innate immune signaling. DNA methylation was associated with altered BRD4 binding at STING regulatory regions. This suppression weakened the immune response triggered by poly (ADP-ribose) polymerase inhibitors (PARPi) through STING downregulation. Conclusion Our findings revealed a complex, context-dependent regulation of tumor immunity by BETi, characterized by the suppression of STING-mediated responses. These results suggest that BETi may dampen immune activation induced by PARPi by decreasing STING expression. Optimizing therapeutic strategies for the combined use of BETi and PARPi are crucial to balance their effects and maximize clinical benefits.